Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

NCT01253525 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenocarcinoma

Interventions

BIOLOGICAL: Ramucirumab (IMC-1121B )
DRUG: Paclitaxel

Sponsor

Eli Lilly and Company